
    
      PRIMARY OBJECTIVES:

      I. To evaluate 68Ga-PSMA-11 PET/CT for detection of recurrent prostate cancer after initial
      therapy in patients with elevated PSA.

      Eligible participants will undergo baseline assessments at enrollment. Study participants
      will receive 68Ga PSMA 11 and undergo a PET/CT. Participants will be contacted at 24 to 72
      hours following the scan in order to capture potential late occurring Adverse Events.Clinical
      follow up of participant at 3 to 12 months following the scan in order to analyze secondary
      endpoints.
    
  